No Detail Found!

Checkpoint Inhibitors: A novel approach in the avenues for cancer therapy

Author(s)
Vaishnavi Bose RAK College of Medical Sciences (RAKCOMS), RAK Medical & Health Sciences University (RAKMHSU),Ras al Khaimah,United Arab Emirates
Shriya Devendra Tayade RAK College of Medical Sciences (RAKCOMS), RAK Medical & Health Sciences University (RAKMHSU),Ras al Khaimah,United Arab Emirates
Ashna Ameer RAK College of Medical Sciences (RAKCOMS), RAK Medical & Health Sciences University (RAKMHSU),Ras al Khaimah,United Arab Emirates
Pooja Mahesh Sikotra RAK College of Medical Sciences (RAKCOMS), RAK Medical & Health Sciences University (RAKMHSU),Ras al Khaimah,United Arab Emirates
Godfred A. Menezes RAK College of Medical Sciences (RAKCOMS), RAK Medical & Health Sciences University (RAKMHSU),Ras al Khaimah,United Arab Emirates
Abstract
Cancer has been on the rise in the Middle East and North African region. There is a need for newer, targeted therapies to combat this trend. Cancer growth and progression are intricately associated with immune suppression and checkpoint inhibitors, that target this immune suppression, presenting a novel treatment avenue. The aim of this review is to summarize the fundamentals and highlight the future of checkpoint inhibitors in cancer therapy. PubMed, SCOPUS and index journals were searched based on key concepts related to checkpoint inhibitors and narrowed down from 2015 to 2021, to present only the most recent and relevant information. The development of immune checkpoint inhibitors is a revolutionary milestone in the field of immuno-oncology. The immune system recognizes and is poised to eliminate cancer but tumors have numerous ways of suppressing the antitumor immune response and upregulation of co-inhibitory receptors, known as immune checkpoints, is a key mechanism in the same. These immune checkpoint pathways normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses but they are used by cancer to evade immune destruction. Drugs interrupting immune checkpoints can thus revive antitumor immune responses by interrupting co-inhibitory signaling pathways and promote immune-mediated elimination of tumor cells. Checkpoint inhibitors are considered to be an effective new addition to the available therapies with a clear role in the first-line treatment of advanced melanoma and in the second-line treatment of advanced squamous non- small cell lung cancers. The review describes the underlying principles of checkpoint blockade, its potential in cancer therapy and the current approved drugs. Combination regimens and recent progress in treatment models have also been briefed in the article. Therapies utilizing checkpoint inhibitors have potent implications in the treatment of specific types of cancers and the continuing research in the field can contribute immensely to better understanding of tumor mechanisms and immunity.
Publication Details
Page(s) 250-256
DOI DOI not available
Published Journal: Bioscience Research, Volume: 19, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
CTLA-4, Immune Therapy, PD-1, Immune Checkpoints, Combination Cancer Therapy, Checkpoint Inhibitors
0

Citations

0

Downloads

30

Views